- Home
- TEX vs NAMS Comparison
TEX vs NAMS Comparison
Compare TEX & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEX
- NAMS
- Stock Information
- Founded
- TEX 1933
- NAMS 2019
- Country
- TEX United States
- NAMS Netherlands
- Employees
- TEX N/A
- NAMS N/A
- Industry
- TEX Construction/Ag Equipment/Trucks
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- TEX Industrials
- NAMS Health Care
- Exchange
- TEX Nasdaq
- NAMS Nasdaq
- Market Cap
- TEX 3.0B
- NAMS 2.7B
- IPO Year
- TEX N/A
- NAMS N/A
- Fundamental
- Price
- TEX $47.21
- NAMS $23.55
- Analyst Decision
- TEX Hold
- NAMS Strong Buy
- Analyst Count
- TEX 12
- NAMS 7
- Target Price
- TEX $57.82
- NAMS $38.17
- AVG Volume (30 Days)
- TEX 763.5K
- NAMS 581.4K
- Earning Date
- TEX 02-06-2025
- NAMS 02-06-2025
- Dividend Yield
- TEX 1.44%
- NAMS N/A
- EPS Growth
- TEX N/A
- NAMS N/A
- EPS
- TEX 6.84
- NAMS N/A
- Revenue
- TEX $5,108,500,000.00
- NAMS $33,594,000.00
- Revenue This Year
- TEX $0.30
- NAMS $131.53
- Revenue Next Year
- TEX $6.21
- NAMS N/A
- P/E Ratio
- TEX $6.89
- NAMS N/A
- Revenue Growth
- TEX N/A
- NAMS 78.77
- 52 Week Low
- TEX $43.50
- NAMS $15.19
- 52 Week High
- TEX $68.08
- NAMS $27.29
- Technical
- Relative Strength Index (RSI)
- TEX 49.98
- NAMS 44.17
- Support Level
- TEX $43.50
- NAMS $22.53
- Resistance Level
- TEX $46.80
- NAMS $26.71
- Average True Range (ATR)
- TEX 1.26
- NAMS 0.97
- MACD
- TEX 0.53
- NAMS -0.45
- Stochastic Oscillator
- TEX 79.10
- NAMS 23.89
About TEX Terex Corporation
Terex is a top manufacturer of aerial work platforms, materials processing equipment, and specialty equipment, such as material handlers, cranes, and concrete mixer trucks. Its current composition is a result of numerous acquisitions over several decades and a recent shift to focus on its two core segments after divesting a handful of underperforming businesses. Terex's remaining segments see heavy demand in nonresidential construction as well as in maintenance, manufacturing, energy, and materials management.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.